---
title: "Valion Bio (VBIO) news: reverse split and offering"
url: "https://aibio.space/companies/valion-bio/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "VBIO reverse split, offering, convertible notes and settlement news: Valion sets 1-for-25 reverse stock split to regain Nasdaq compliance. Valion Bio, Inc."
---

VBIO Valion Bio, Inc. NASDAQ · United States

# Valion Bio (VBIO) news VBIO reverse split, offering and convertible notes news

Financings · 2026-10-27

## [Valion Bio sells preferred stock, mostly to settle overdue Series C payments](https://aibio.space/news/valion-bio-sells-preferred-stock-mostly-settle-overdue-series/)

Valion Bio sold 4,717.73 Series C preferred shares for $4,717,717.61, but $3,217,717.61 of that stays with the buyers to cover overdue cash true-up payments. The company receives $1,500,000 in cash.

## Latest Valion Bio news

1. 2026-10-15 Company Updates [Velocity Bioworks completes NMR feasibility test with LarmorBio](https://aibio.space/news/velocity-bioworks-completes-nmr-feasibility-test-larmorbio/) Valion's CDMO unit finished an initial evaluation of LarmorBio's BioScan-NMR platform for continuous bioprocess monitoring.
2. 2026-10-08 Financings [Valion Bio files $100,000,000 shelf with $5,000,000 at-the-market program](https://aibio.space/news/valion-bio-files-100-000-000-shelf-5-000-000-market-program/) Valion Bio filed a $100,000,000 shelf registration on October 7, 2026, and the same day agreed to sell 3i $50,000 of Series B preferred and warrants. The public float used for the shelf was based on a $7.75 price, while the last reported sale on October 5 was $2.48.
3. 2026-09-30 Company Updates [Valion and SKL complete oral mucosal Entolimod formulation](https://aibio.space/news/valion-skl-complete-oral-mucosal-entolimod-formulation/) Valion and Shear Kershman Laboratories finished formulation work on a needle-free Entolimod, with systemic exposure testing next.
4. 2026-09-23 Company Updates [Valion names Dean Zikria interim CEO and changes board chair](https://aibio.space/news/valion-names-dean-zikria-interim-ceo-changes-board-chair/) Board member Dean Zikria becomes interim chief executive officer, Thomas Jensen takes the board chair, and Lisa Wolf keeps her roles.
5. 2026-08-27 Listings [Valion sets 1-for-25 reverse stock split to regain Nasdaq compliance](https://aibio.space/news/valion-sets-1-25-reverse-stock-split-regain-nasdaq-compliance/) The split takes effect August 31, 2026 under the same VBIO symbol, and the company says it aims to meet the Nasdaq minimum bid price rule.
6. 2025-12-11 Mergers [Tivic Health Systems (now Valion Bio) buys Scorpius CDMO assets for $16,253,147.10](https://aibio.space/news/tivic-health-systems-now-valion-bio-buys-scorpius-cdmo-assets-16-253/) Tivic Health Systems bought the manufacturing and development assets of Scorpius Holdings at a public auction, paying $16,253,147.10 in cash funded by a senior secured convertible note sold to 3i. The note converts at a fixed price and at a discount to market, which can add shares.
7. 2025-05-15 Listings [Tivic Health (now Valion Bio) ends quarter with $669,000 cash, lines up financing](https://aibio.space/news/tivic-health-now-valion-bio-ends-quarter-669-000-cash-lines-up/) Tivic reported $669,000 of cash at March 31, 2025 and a $1.5 million net loss for the quarter. It then lined up a $25 million equity line and a purchase agreement for up to $8.4 million of securities.

## Valion Bio at a glance

- **Ticker**: VBIO

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $2.1 million

### Related companies

- [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT
- [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI
- [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG
- [Alpha Cognition](https://aibio.space/companies/alpha-cognition/) NASDAQ: ACOG
- [Nutriband](https://aibio.space/companies/nutriband/) NASDAQ: NTRB
- [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX
- [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) AMEX: SER
- [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO

### Also on NASDAQ

- [City Therapeutics](https://aibio.space/companies/city-therapeutics/) CTY
- [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) AYTU
- [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) SYRE
- [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) KRYS
- [ASP Isotopes](https://aibio.space/companies/asp-isotopes/) ASPI
- [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) BRVE

## Valion Bio annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue |  | [$780,000](https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/) |
| Research and development | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) |
| Net income (loss) | [-$8.9 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) | [-$5.7 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) |
| Cash from operations | [-$7.0 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) | [-$5.7 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) |
| Cash and equivalents | [$12.6 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926028069/) | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Valion Bio

Did Valion Bio do a reverse stock split?

Our latest story on this, dated Aug 27, 2026: "Valion sets 1-for-25 reverse stock split to regain Nasdaq compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/valion-sets-1-25-reverse-stock-split-regain-nasdaq-compliance/).

Has Valion Bio raised money recently?

Our latest story on this, dated Oct 8, 2026: "Valion Bio files $100,000,000 shelf with $5,000,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/valion-bio-files-100-000-000-shelf-5-000-000-market-program/).

Has Valion Bio sold convertible notes?

Our latest story on this, dated Dec 11, 2025: "Tivic Health Systems (now Valion Bio) buys Scorpius CDMO assets for $16,253,147.10". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tivic-health-systems-now-valion-bio-buys-scorpius-cdmo-assets-16-253/).

Has Valion Bio settled a lawsuit?

Our latest story on this, dated Oct 27, 2026: "Valion Bio sells preferred stock, mostly to settle overdue Series C payments". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/valion-bio-sells-preferred-stock-mostly-settle-overdue-series/).

What is the ticker symbol of Valion Bio?

Valion Bio, Inc. trades under the ticker VBIO on NASDAQ.

Where is Valion Bio listed?

Valion Bio, Inc. is listed on NASDAQ.

What is the SEC CIK of Valion Bio?

The SEC Central Index Key (CIK) for Valion Bio, Inc. is 1787740. Its filings are on SEC EDGAR.

How many shares does Valion Bio have outstanding?

22,189,739 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Valion Bio listed under?

Our directory records Valion Bio, Inc. under United States.

What does Valion Bio do?

Our directory classifies Valion Bio, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.

What is the ISIN of Valion Bio?

The ISIN recorded for Valion Bio, Inc. is US9189422028.

Does aibio.space cover Valion Bio?

aibio.space lists Valion Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Valion Bio incorporated?

SEC records list its state or country of incorporation as DE.

Is Valion Bio profitable?

Valion Bio, Inc. reported a net loss of $8.9 million for the fiscal year ended Dec 31, 2025, and used $7.0 million of cash in operations, per its annual report to the SEC.

How much does Valion Bio spend on research and development?

$3.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: Valion Bio

Members talk about Valion Bio (VBIO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Valion Bio, newest first. Each line links the filing it comes from.

1. 2026-10-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000143774926033552/vbio20261023_8k.htm)
2. 2026-10-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007932/valion_def14a.htm)
3. 2026-10-08 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007707/valion_s3.htm)
4. 2026-10-02 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007588/valion_pre14a.htm)
5. 2026-09-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/valion_ex9901.htm)
6. 2026-08-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826006742/valion_ex9901.htm)
7. 2026-08-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/valion_8k.htm)
8. 2026-08-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826006049/valion_8k.htm)
9. 2026-07-17 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826005613/valion_s1.htm)
10. 2026-07-17 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826005615/valion_def14a.htm)
11. 2026-07-07 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826005335/valion_pre14a.htm)
12. 2026-06-18 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826004956/valion_8k.htm)
13. 2026-03-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm)
14. 2026-03-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826002064/tivic_8k.htm)
15. 2026-02-09 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316826000877/tivic_8k.htm)
16. 2025-12-11 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,2.03,3.02,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316825009079/tivic_ex9901.htm)
17. 2025-11-14 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/tivc20250909_8k.htm)
18. 2025-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/tivc-ex99_1.htm)
19. 2025-05-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025062733/tivc-20250429.htm)
20. 2025-04-14 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025053769/tivc-20250414.htm)
21. 2025-04-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025052679/tivc-ex99_1.htm)
22. 2025-04-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025050485/tivc-20250328.htm)
23. 2025-03-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/tivc-ex99_1.htm)
24. 2025-03-21 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm)
25. 2025-03-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025033091/tivc-ex99_1.htm)
26. 2025-02-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/tivc-ex99_1.htm)
27. 2025-02-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/tivc-ex99_1.htm)
28. 2025-02-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025014601/tivc-20250131.htm)
29. 2025-01-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/tivc-20241227.htm)
30. 2025-01-03 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787740/000168316825000065/tivic_def14a.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VBIO on TradingView](https://www.tradingview.com/symbols/NASDAQ-VBIO/).

## SEC filings and registration

- **SEC name**: Valion Bio, Inc.

- **CIK**: 1787740

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: VBIO (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 1305 E. HOUSTON STREET, SAN ANTONIO, TX, 78205

- **Phone**: (888)276-6888

- **Shares outstanding**: 22,189,739 as of 2026-08-13 (10-Q filed 2026-08-14)

- **Former names**: Tivic Health Systems, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1787740/000143774926033175/vbio20261021_8k.htm) filed 2026-10-22
- [S-3](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007936/valion_s3.htm) filed 2026-10-16
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007932/valion_def14a.htm) filed 2026-10-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007857/valion_8k.htm) filed 2026-10-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/valion_8k.htm) filed 2026-10-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007709/valion_8k.htm) filed 2026-10-08
- [S-3](https://www.sec.gov/Archives/edgar/data/1787740/000168316826007707/valion_s3.htm) filed 2026-10-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/vbio20261005_8k.htm) filed 2026-10-06

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001787740), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Valion Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VBIO, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Valion Bio, Inc.

- **Ticker**: VBIO

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biopharma / pharmaceuticals

- **ISIN**: US9189422028

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VBIO/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/valion-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Valion Bio (VBIO) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/valion-bio/